US activists called on Gilead to set a per-treatment price for sofosbuvir/ledipasvir
In a press release on 13th October 2014, the Fair Pricing Coalition, a US treatment activist organisation, called for Gilead to set a single uniform per-cure price for the coformulation of sofosbuvir and ledipasvir (brand name Harvoni) irrespective or whether 8, 12, or 24 weeks of treatment is required.
“The FPC, a coalition of HIV and viral hepatitis treatment activists, recognises the significant advance in treatment success and convenience of Harvoni, but is disappointed at the Wholesale Acquisition Cost (WAC) of $1,125 per once-daily tablet, or $63,000, $94,500, and $189,000 for an 8-, 12-, and 24-week course of treatment, respectively.”
“The FPC maintains that these costs, particularly for the 12- and 24- week courses of treatment, are exorbitant. Since they are now published, however, FPC concludes that the WAC of $63,000 for eight weeks of Harvoni, which is projected to be the most common duration of treatment as more people living with genotype 1 hepatitis C learn of their infection and seek care, should be made the uniform cost per cure, regardless of the length of therapy.”
Fair Pricing Coalition. Fair Pricing Coalition welcomes approval of Gilead Sciences’ combination tablet for hepatitis C, urges a uniform price for curative treatment. (13 October 2014).